Evidence map›Paper›PMID 34117074›Full record

ArticleCold Spring Harbor molecular case studies2021

Incidental identification of inv(16)(p13.1q22)/

Andrés E Quesada, Rajyalakshmi Luthra, Elias Jabbour, Keyur P Patel, Joseph D Khoury, Zhenya Tang, Hector Alvarez, Saradhi Mallampati, Guillermo Garcia-Manero, Guillermo Montalban-Bravo and 2 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Andrés E QuesadaDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.ORCID 0000-0002-5304-7828
Rajyalakshmi LuthraDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Elias JabbourDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Keyur P PatelDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Joseph D KhouryDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Zhenya TangDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Hector AlvarezDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Saradhi MallampatiDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Guillermo Montalban-BravoDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
L Jeffrey MedeirosDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Rashmi Kanagal-ShamannaDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 52-yr-old woman presented with therapy-related acute myeloid leukemia. A bone marrow biopsy showed 21% blasts with a myeloid phenotype and no other notable features such as abnormal eosinophils. Routine nanofluidics-based reverse transcriptase polymerase chain reaction (PCR) leukemia translocation panel designed to screen for recurrent genetic abnormalities in acute leukemia detected an inversion 16 transcript variant E. This prompted rereview of karyotype and fluorescence in situ hybridization studies, which confirmed inv(16), leading to appropriate prognostication and modification of treatment. This case underscores the utility of a powerful molecular screening method for the routine detection of recurrent genetic abnormalities of acute myeloid leukemia. It was especially useful in this case because of the lack of characteristic morphologic findings seen in inversion 16 and the difficulty in its detection by conventional karyotype analysis.

Indexed as

Translocation, GeneticBone MarrowChromosome InversionChromosomes, Human, Pair 16Core Binding Factor beta SubunitFemaleHematologic NeoplasmsHumansIn Situ Hybridization, FluorescenceLeukemia, Myeloid, AcuteMiddle AgedMyosin Heavy ChainsOncogene Proteins, FusionCBFB protein, humanCore Binding Factor beta SubunitMYH11 protein, humanMyosin Heavy ChainsOncogene Proteins, Fusionacute myeloid leukemiahematological neoplasm

Identifiers

PMID34117074
PMCPMC8208042
OpenAlexW3171188092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.